Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Common Equity (2016 - 2025)

IGC Pharma (IGC) has disclosed Common Equity for 15 consecutive years, with $8.1 million as the latest value for Q3 2025.

  • Quarterly Common Equity rose 9.69% to $8.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $8.1 million through Sep 2025, up 9.69% year-over-year, with the annual reading at $6.3 million for FY2025, 13.54% down from the prior year.
  • Common Equity for Q3 2025 was $8.1 million at IGC Pharma, up from $6.1 million in the prior quarter.
  • The five-year high for Common Equity was $32.8 million in Q1 2021, with the low at $6.1 million in Q2 2025.
  • Average Common Equity over 5 years is $16.3 million, with a median of $14.1 million recorded in 2023.
  • The sharpest move saw Common Equity soared 37.27% in 2021, then plummeted 50.9% in 2024.
  • Over 5 years, Common Equity stood at $29.5 million in 2021, then crashed by 37.86% to $18.3 million in 2022, then plummeted by 50.58% to $9.1 million in 2023, then plummeted by 30.86% to $6.3 million in 2024, then grew by 29.29% to $8.1 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $8.1 million, $6.1 million, and $6.3 million for Q3 2025, Q2 2025, and Q1 2025 respectively.